Current Infectious Disease Reports

, Volume 4, Issue 4, pp 285–292 | Cite as

Cardiac transplantation: Pre-transplant infectious diseases evaluation and post-transplant prophylaxis

  • Susan Keay
Article

Abstract

Screening of recipients and donors of cardiac allografts for infectious pathogens, and the use of appropriate immunization and antimicrobial prophylaxis strategies, remain important for the control of infection following heart transplantation. However, the risk of infectious complications in a particular patient must often be weighed against the risk of delaying or denying allograft transplantation. In addition, the ongoing degree of immunosuppression and its contribution to the risk for infectious complications should also be considered to guide the length of prophylactic antimicrobial therapy and provide optimal patient care.

Keywords

Transplant Recipient Ganciclovir Cardiac Allograft Organ Transplant Recipient Heart Transplant Recipient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Montoya JG, Giraldo LF, Efron B, et al.: Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001, 33:629–640. A retrospective analysis of infectious complications at a major heart transplant center, with review of the influence of changes in immunosuppression and prophylactic regimens on incidence of disease.PubMedCrossRefGoogle Scholar
  2. 2.
    Smart FW, Naftel DC, Costanzo MR, et al.: Risk factors for early, cumulative, and fatal infections after heart transplantation: a multi-institutional study. J Heart Lung Transplant 1996, 15:329–341.PubMedGoogle Scholar
  3. 3.
    De Maria R, Minoli L, Parolini M, et al.: Prognostic determinations of six-month morbidity and mortality in heart transplant recipients. J Heart Lung Transplant 1996, 15:124–135.PubMedGoogle Scholar
  4. 4.
    Prendergast TW, Todd BA, Beyer JA III, et al.: Management of left ventricular assist device infection with heart transplantation. Ann Thorac Surg 1997, 64:142–147.PubMedCrossRefGoogle Scholar
  5. 5.
    Krogsgaard K, Boesgaard S, Aldershvile J, et al.: Cytomegalovirus infection rate among heart transplant patients in relation to anti-thymocyte immunoglobulin induction therapy. Scand J Infect Dis 1994, 26:239–247.PubMedGoogle Scholar
  6. 6.
    De Waele M, Naessens A, Foulon W, van Camp B: Activated Tcells with suppressor/cytotoxic phenotype in acute Toxoplasma gondii infection. Clin Exp Immunol 1985, 62:256–261.PubMedGoogle Scholar
  7. 7.
    Gottesdiener KM: Transplant infections: Donor-to-host transmission with the allograft. Ann Intern Med 1989, 110:1001–1016.PubMedGoogle Scholar
  8. 8.
    Fall AJ, Aitchison JD, Krause A, et al.: Donor organ transmission of varicella zoster due to cardiac transplantation. Transplantation 2000, 70:211–213.PubMedGoogle Scholar
  9. 9.
    Goodman JL: Possible transmission of herpes simplex virus by organ transplantation. Transplantation 1989, 47:609–613.PubMedCrossRefGoogle Scholar
  10. 10.
    Preiksaitis JK, Rosno S, Grumet C, Merigan TC: Infections due to herpesviruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy. J Infect Dis 1983, 147:974–981.PubMedGoogle Scholar
  11. 11.
    Zibari GB, Lipka J, Zizzi H, et al.: The use of contaminated donor organs in transplantation. Clin Transplant 2000, 14:397–400.PubMedCrossRefGoogle Scholar
  12. 12.
    Coll P, Montserrat I, Ballester M, et al.: Epidemiologic evidence of transmission of donor-related bacterial infection through a transplanted heart. J Heart Lung Transplant 1997, 16:464–467.PubMedGoogle Scholar
  13. 13.
    Pfau PR, Rho R, DeNofrio D, et al.: Hepatitis C transmission and infection by orthotopic heart transplantation. J Heart Lung Transplant 2000, 19:350–354.PubMedCrossRefGoogle Scholar
  14. 14.
    Ko WJ, Chou NK, Hsu RB, et al.: Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area. J Heart Lung Transplant 2001, 20:865–875. Retrospective review of outcomes for heart transplant patients with primary, secondary, or reactivated HBV infection in an endemic area.PubMedCrossRefGoogle Scholar
  15. 15.
    Fischer L, Sterneck M, Claus M, et al.: Transmission of malaria tertiana by multi-organ donation. Clin Transplant 1999, 13:491–495.PubMedCrossRefGoogle Scholar
  16. 16.
    Luft BJ, Naot Y, Araujo FG, et al.: Primary and reactivated Toxoplasma infection in patients with cardiac transplants: clinical spectrum and problems in diagnosis in a defined population. Ann Intern Med 1983, 99:27–31.PubMedGoogle Scholar
  17. 17.
    Keating MR, Guerrero MA, Daly RC, et al.: Transmission of invasive aspergillosis from a subclinically infected donor to three different organ transplant recipients. Chest 1996, 109:1119–1124.PubMedGoogle Scholar
  18. 18.
    van der Vliet JA, Tidow G, Kootstra G, et al.: Transplantation of contaminated organs. Br J Surg 1980, 67:596–598.PubMedCrossRefGoogle Scholar
  19. 19.
    Simonds RJ: HIV transmission by organ and tissue transplantation. AIDS 1993, 7(Suppl 2):S35-S38.PubMedCrossRefGoogle Scholar
  20. 20.
    Lumbreras C, Sanz F, Gonzalez A, et al.: Clinical significance of donor-unrecognized bacteremia in the outcome of solidorgan transplant recipients. Clin Infect Dis 2001, 33:722–726.PubMedCrossRefGoogle Scholar
  21. 21.
    Lammermeier DE, Sweeney MS, Haupt HE, et al.: Use of potentially infected donor hearts for cardiac transplantation. Ann Thorac Surg 1990, 50:222–225.PubMedCrossRefGoogle Scholar
  22. 22.
    Bull DA, Stahl RD, McMahan DL, et al.: The high risk heart donor:potential pitfalls. J Heart Lung Transplant 1995, 14:424–428.PubMedGoogle Scholar
  23. 23.
    Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccine and immune globulins for persons with altered immunocompetence. MMWR Morb Mortal Wkly Rep 1993, 42(RR-4):1–18.Google Scholar
  24. 24.
    Pirofski LA, Casadevall A: Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev 1998, 11:1–26.PubMedGoogle Scholar
  25. 25.
    Burroughs M, Mascona A: Immunization of pediatric solid organ transplant candidates and recipients. Clin Infect Dis 2000, 30:857–869.PubMedCrossRefGoogle Scholar
  26. 26.
    Wagner D, Wagenbreth I, Stachan-Kunstyr R, et al.: Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and D gene products. Clin Invest 1994, 72:350–352.Google Scholar
  27. 27.
    Avery RK, Ljungman P: Prophylactic measures in the solidorgan recipient before transplantation. Clin Infect Dis 2001, 33 (Suppl 1):S15-S21. Comprehensive review of immunization strategies for solid organ transplant patients.PubMedCrossRefGoogle Scholar
  28. 28.
    Bocchi EA, Fiorelli A: The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. Ann Thorac Surg 2001, 71:1833–1836.PubMedCrossRefGoogle Scholar
  29. 29.
    Golino A, Duncan JM, Zeluff B, et al.: Leischmaniasis in a heart transplant patient. J Heart Lung Transplant 1992, 11:820–823.PubMedGoogle Scholar
  30. 30.
    Myers TJ, Khan T, Frazier OH: Infectious complications associated with ventricular assist systems. ASAIO J 2000, 46:S28-S36.PubMedCrossRefGoogle Scholar
  31. 31.
    Sinha P, Chen JM, Flannery M, et al.: Infections during left ventricular assist device support do not affect posttransplant outcomes. Circulation 2000, 102(Suppl 3):194–199. Retrospective nonrandomized, controlled study to examine the impact of left ventricular assist devices on infection-related patient outcomes after heart transplant.Google Scholar
  32. 32.
    Delmonico FL: Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis 2000, 31:781–786. Review of infections commonly transmitted by an infected solid organ donor, including data on hepatitis B virus and hepatitis C virus transmission in heart transplant patients.PubMedCrossRefGoogle Scholar
  33. 33.
    Schaffner A: Pre-transplant evaluation for infections in donors and recipients of solid organs. Clin Infect Dis 2001, 33(Suppl 1):S9-S14. Comprehensive review of donor and recipient screening strategies for solid organ transplant patients. Includes suggested criteria for rejecting or accepting transplant in situations with an infected donor or recipient.PubMedCrossRefGoogle Scholar
  34. 34.
    Simonds RJ, Holmberg SD, Hurwitz RL, et al.: Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. N Engl J Med 1992, 326:726–732.PubMedCrossRefGoogle Scholar
  35. 35.
    Gout O, Baulac M, Gessain A, et al.: Rapid development of myelopathy after HTLV-1 infection acquired by transfusion during cardiac transplantation. N Engl J Med 1990, 322:383–388.PubMedCrossRefGoogle Scholar
  36. 36.
    Keay S, Oldach D, Redfield R, Bartlett S: Organ transplantation in the HIV-infected patient. Curr Opin Organ Transplant 2000, 5:217–223.CrossRefGoogle Scholar
  37. 37.
    Fishman JA, Rubin RH: Infection in organ-transplant recipients. N Engl J Med 1998, 338:1741–1751.PubMedCrossRefGoogle Scholar
  38. 38.
    Grattan MT, Moreno-Cabral CE, Starnes VA, et al.: Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989, 261:3561–3566.PubMedCrossRefGoogle Scholar
  39. 39.
    Mattila PS, Aalto SM, Heikkila L, et al.: Malignancies after heart transplantation: presence of Epstein-Barr virus and cytomegalovirus. Clin Transplant 2001, 15:337–342.PubMedCrossRefGoogle Scholar
  40. 40.
    Rubin RH: Prevention and treatment of cytomegalovirus disease in heart transplant patients. J Heart Lung Transplant 2000, 19:731–735. Review of currently available treatment strategies for CMV in heart transplant patients.PubMedCrossRefGoogle Scholar
  41. 41.
    Pamphilon DH, Rider JR, Barbara JA, Williamson LM: Prevention of transfusion-transmitted cytomegalovirus infection. Transfus Med 1999, 9:115–123.PubMedCrossRefGoogle Scholar
  42. 42.
    Preiksaitis JK, Keay S: Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant patients. Clin Infect Dis 2001, 33(Suppl 1):S38-S46.PubMedCrossRefGoogle Scholar
  43. 43.
    Moschettini D, De Milito A, Catucci M, et al.: Detection of human herpesviruses 6 and 7 in heart transplant recipients by a multiplex polymerase chain reaction method. Eur J Clin Microbiol Infect Dis 1998, 17:117–119.PubMedGoogle Scholar
  44. 44.
    Farge D: Kaposi’s sarcoma in organ transplant recipients. Eur J Med 1993, 2:339–343.PubMedGoogle Scholar
  45. 45.
    Drescher J, Wagner D, Haverich A, et al.: Nosocomial hepatitis B virus infections in cardiac transplant recipients transmitted during transvenous endomyocardial biopsy. J Hosp Infect 1994, 26:81–92.PubMedCrossRefGoogle Scholar
  46. 46.
    Wedemeyer H, Pethig K, Wagner D, et al.: Long-term outcome of chronic hepatitis B in heart transplant recipients. Transplantation 1998, 66:1347–1353.PubMedCrossRefGoogle Scholar
  47. 47.
    Lunel F, Cadranel JF, Rosenheim M, et al.: Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology 2000, 119:1064–1074.PubMedGoogle Scholar
  48. 48.
    Wachs ME, Amend WJ, Ascher NL, et al.: The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995, 59:230–234.PubMedCrossRefGoogle Scholar
  49. 49.
    Hosenpud JD, Pamidi SR, Fiol BS, et al.: Outcomes in patients who are hepatitis B surface antigen-positive before transplantation: an analysis and study using the joint ISHLT/UNOS thoracic registry. J Heart Lung Transplant 2000, 19:781–785.PubMedCrossRefGoogle Scholar
  50. 50.
    Turik MA, Markowitz SM: A successful regimen for the prevention of seroconversion after transplantation of a heart positive for hepatitis B surface antigen. J Heart Lung Transplant 1992, 11:781–783.PubMedGoogle Scholar
  51. 51.
    Pereira B, Levey A: Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997, 51:981–989.PubMedCrossRefGoogle Scholar
  52. 52.
    Wreghitt TG, Gray JJ, Allain JP, et al.: Transmission of hepatitic C by organ transplantation in the United Kingdom. J Hepatol 1994, 20:768–772.PubMedCrossRefGoogle Scholar
  53. 53.
    Araya V, Rakela J, Wright T: Hepatitis C after orthotopic liver transplantation. Gastroenterology 1997, 112:575–582.PubMedCrossRefGoogle Scholar
  54. 54.
    Michaels MG, Wald ER, Fricker FJ, et al.: Toxoplasmosis in pediatric recipients of heart transplants. Clin Infect Dis 1992, 14:847–851.PubMedGoogle Scholar
  55. 55.
    Orr KE, Gould FK, Short G, et al.: Outcome of toxoplasma gondii mismatches in heart transplant recipients over a period of 8 years. J Infect 1994, 29:249–253.PubMedCrossRefGoogle Scholar
  56. 56.
    Gallino A, Maggiorini M, Kiowski W, et al.: Toxoplasmosis in heart transplant recipients. Eur J Clin Microbiol Infect Dis 1996, 15:389–393.PubMedCrossRefGoogle Scholar
  57. 57.
    Ko WJ, Chu SH, Lee YH, et al.: Successful prevention of syphilis transmission from a multiple organ donor with serlogical evidence of syphilis. Transplant Proc 1998, 30:3667–3668.PubMedCrossRefGoogle Scholar
  58. 58.
    Caballero F, Domingo P, Rabella N, Lopez-Navidad A: Successful transplantation of organs retrieved from a donor with syphilis. Transplantation 1998, 65:598–599.PubMedCrossRefGoogle Scholar
  59. 59.
    Dooley DP, Beckius ML, Jeffery BS, et al.: Phaeohyphomycotic cutaneous disease caused by Pleurophoma in a cardiac transplant patient. J Infect Dis 1989, 159:503–507.PubMedGoogle Scholar
  60. 60.
    Gerdsen R, Uerlich M, De Hong GS, et al.: Sporotrichoid phaeohyphomycosis due to Alternaria infectoria. Br J Dermatol 2001, 145:484–486.PubMedCrossRefGoogle Scholar
  61. 61.
    Sampathkumar P, Paya C: Fusarium infection after solidorgan transplantation. Clin Infect Dis 2001, 32:1237–1240.PubMedCrossRefGoogle Scholar
  62. 62.
    Koide M, Arakaki N, Saito A: Distribution of Legionella longbeachae and other legionellae in Japanese potting soils. J Infect Chemother 2001, 7:224–227.PubMedCrossRefGoogle Scholar
  63. 63.
    Soave R: Prophylaxis strategies for solid-organ transplantation. Clin Infect Dis 2001, 33(Suppl 1):S26-S31. Comprehensive review of general antimicrobial treatment strategies in solid organ transplant patients.PubMedCrossRefGoogle Scholar
  64. 64.
    Rubin RH, Tolkoff-Rubin NE: Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother 1993, 37:619–624.PubMedGoogle Scholar
  65. 65.
    Merigan TC, Renlund DG, Keay S, et al.: A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992, 326:1182–1186.PubMedCrossRefGoogle Scholar
  66. 66.
    Valantine HA, Gao SZ, Menon SG, et al.: Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placeo-controlled study. Circulation 1999, 100:61–66.PubMedGoogle Scholar
  67. 67.
    Valantine HA, Luikart H, Doyle R, et al.: Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001, 72:1647–1652.PubMedCrossRefGoogle Scholar
  68. 68.
    Metselaar HJ, Balk AH, Mochtar B, et al.: Cytomegalovirus seronegative heart transplant recipients. Prophylactic use of anti-CMV immunoglobulin. Chest 1990, 97:396–399.PubMedGoogle Scholar
  69. 69.
    Va der Bij W, Speich R: Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis 2001, 33(Suppl 1):S33-S37. General review of diagnostic, prophylactic, and treatment strategies for CMV disease in solid organ transplant recipients.Google Scholar
  70. 70.
    Rubin RH, Kemmerly SA, Conti D, et al.: Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transplant Infect Dis 2000, 2:112–117.Google Scholar
  71. 71.
    Baldanti F, Simoncini L, Sarasini A, et al.: Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation 1998, 66:324–329.PubMedCrossRefGoogle Scholar
  72. 72.
    Avery RK: Prevention and treatment of cytomegalovirus infection and disease in heart transplant recipients. Curr Opin Cardiol 1998, 13:122–129.PubMedCrossRefGoogle Scholar
  73. 73.
    Kunzle N, Petignat D, Francioli P, et al.: Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients:relationship between compliance with the guidelines and prevention of CMV morbidity. Transplant Infect Dis 2000, 2:118–126.CrossRefGoogle Scholar
  74. 74.
    Ormrod D, Scott LJ, Perry CM: Valacyclovir:a review of its long term utility in the management of genital herpes simplex and cytomegalovirus infections. Drugs 2000, 59:839–863.PubMedCrossRefGoogle Scholar
  75. 75.
    Hummel M, Thalmann U, Jautzke G, et al.: Fungal infections following heart transplantation. Mycoses 1992, 35:23–34.PubMedCrossRefGoogle Scholar
  76. 76.
    Paya CV: Prevention of fungal and hepatitis virus infections in liver transplantation. Clin Infect Dis 2001, 33(Suppl 1):S47-S52.PubMedCrossRefGoogle Scholar
  77. 77.
    Winston DJ, Pakrasi A, Busuttil RW: Prophylactic fluconazole in liver transplant recipients: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 131:729–737.PubMedGoogle Scholar
  78. 78.
    Keogh A, Spratt P, McCosker C, et al.: Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995, 333:628–633.PubMedCrossRefGoogle Scholar
  79. 79.
    Patterson JE, Peters J, Calhoon JH, et al.: Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transplant Infect Dis 2000, 2:22–28.CrossRefGoogle Scholar
  80. 80.
    Bohme A, Just Nubling G, Bergmann L, et al.: Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1996, 38:953–961.PubMedCrossRefGoogle Scholar
  81. 81.
    Reichenspurner H, Gamberg P, Nitscke M, et al.: Significant reduction in the number of fungal infections after lung-heart-lung- and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997, 29:627–628.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Susan Keay
    • 1
  1. 1.Division of Infectious Diseases, Department of MedicineUniversity of Maryland School of Medicine and Medical Service, VA Maryland Health Care SystemBaltimoreUSA

Personalised recommendations